<unk>  is a program of the United States Food and Drug Administration (FDA) to expedite the<unk>  process for drugs that are expected to have a particularly great impact on the treatment of a disease. The<unk>  voucher program is a program that grants a voucher for<unk>  to a drug developer as an incentive to develop treatments for disease indications with limited profitability.<unk>  vouchers are currently earned by pharmaceutical companies for the development and approval of drugs treating neglected tropical diseases, rare pediatric diseases, and "medical countermeasures" for terrorism. The voucher can be used for future drugs that could have wider indications for use, but the company is required to pay a fee (approximately $2.8 million) to use the voucher. When seeking approval for a drug, manufacturers can apply to the FDA for<unk> . This is granted when a drug is intended to treat a serious condition and would "provide a significant improvement in safety or effectiveness" over currently available treatments. A<unk>  voucher can be used when a drug does not fit these requirements, but the company wishes to expedite the<unk>  process. In 2007, Title XI of the Food and Drug Administration Amendments Act of 2007 created the<unk>  voucher program for neglected tropical diseases. This was extended in 2012 by the Food and Drug Administration Safety and Innovation Act to include rare pediatric diseases. The act built upon the tropical disease system and made amendments including a shorter notification to the FDA before exercising a voucher, a designation system so that early in the drug development cycle sponsors may use the possibility of earning a voucher in their valuation of their company, a requirement of a marketing plan and reporting of marketing, and indefinite transferability of the voucher. In 2016, medical countermeasures was added to the program.
Priority review
Clinical peer review
Risk assessment
Prescription monitoring program
Significant event audit
Rapid reviews
Outbreak response
Incident report